These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9533481)

  • 1. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G; Mascaretti O; Radice M; Power P; Calcagno ML; Mata EG; Gutkind G
    J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
    Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
    Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
    Kalp M; Totir MA; Buynak JD; Carey PR
    J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
    Ohsuka S; Arakawa Y; Horii T; Ito H; Ohta M
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1856-8. PubMed ID: 7486932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
    Bethel CR; Taracila M; Shyr T; Thomson JM; Distler AM; Hujer KM; Hujer AM; Endimiani A; Papp-Wallace K; Bonnet R; Bonomo RA
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3465-75. PubMed ID: 21555770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
    Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
    J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.
    Hedberg M; Lindqvist L; Tunér K; Nord CE
    J Antimicrob Chemother; 1992 Jul; 30(1):17-25. PubMed ID: 1331018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
    Padayatti PS; Helfand MS; Totir MA; Carey MP; Carey PR; Bonomo RA; van den Akker F
    J Biol Chem; 2005 Oct; 280(41):34900-7. PubMed ID: 16055923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed or variable concentrations of beta-lactamase inhibitors in in-vitro tests?
    Greenwood D
    J Antimicrob Chemother; 1996 Jul; 38(1):17-20. PubMed ID: 8858452
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
    Hedberg M; Lindqvist L; Tunér K; Nord CE
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C; Kotra LP; Sanschagrin F; Mobashery S; Levesque RC
    FEBS Lett; 2000 Mar; 470(3):285-92. PubMed ID: 10745083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
    Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
    Franceschini N; Perilli M; Segatore B; Setacci D; Amicosante G; Mazzariol A; Cornaglia G
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1459-62. PubMed ID: 9624494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.
    Ke W; Sampson JM; Ori C; Prati F; Drawz SM; Bethel CR; Bonomo RA; van den Akker F
    Antimicrob Agents Chemother; 2011 Jan; 55(1):174-83. PubMed ID: 21041505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.